CareDx (CDNA) said Friday it has released a proposed draft Local Coverage Determination on molecular testing for solid organ allograft rejection.
There is no change in current coverage and the draft policy is open for comment through Aug. 31, the company said. The proposal also introduces a bundled payment model for surveillance testing.
The company said it is reviewing the draft policy and plans to provide additional information at its earnings call on Aug. 6.
Shares of CareDx were up more than 3% in recent trading.
Price: 12.22, Change: +0.41, Percent Change: +3.47
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。